銅キレート剤クプリゾンは高脂肪食による肥満を抑制する

[Introduction] With the increase of obese and diabetic patients, anti-obesity drugs which decrease fat content without muscle atrophy are expected. In obese or diabetic patients, serum copper concentration was reported to increase compared with that in healthy subjects. However, it is still unknown...

Full description

Saved in:
Bibliographic Details
Published in日本薬理学会年会要旨集 p. 1-O-15
Main Authors 楊, 潔, 三明, 淳一朗, 澤野, 達哉, 今村, 武史, 市原, 克則
Format Journal Article
LanguageJapanese
Published 公益社団法人 日本薬理学会 2019
Online AccessGet full text
ISSN2435-4953
DOI10.1254/jpssuppl.92.0_1-O-15

Cover

More Information
Summary:[Introduction] With the increase of obese and diabetic patients, anti-obesity drugs which decrease fat content without muscle atrophy are expected. In obese or diabetic patients, serum copper concentration was reported to increase compared with that in healthy subjects. However, it is still unknown whether the lowering of serum copper levels has anti-obese effects. Therefore, we investigated the effects of copper chelator, cuprizone on high fat diet (HFD)-induced obesity in mice model.[Method] We administered cuprizone (0.2%w) mixed in food pellet. Mice fed (1) normal chow (NC), (2) NC with cuprizone, (3) HFD or (4) HFD with cuprizone for 4 weeks, and then metabolic parameters were obtained. [Results] Serum copper level was decreased in both cuprizone groups. Cuprizone significantly decreased the body weight extensively in HFD, but slightly in NC fed mice, without changes of food intake. Interestingly, cuprizone specifically decreased 60% of epididymal and inguinal fat weights, but not liver and muscle (soleus and gastrocnemius) weights, only in HFD. Furthermore, HFD-induced glucose intolerance (ipGTT) and insulin resistance (ITT) were significantly improved by cuprizone[Conclusion] Cuprizone inhibited HFD-induced adiposity via the decreased amount of fat depot.
Bibliography:92_1-O-15
ISSN:2435-4953
DOI:10.1254/jpssuppl.92.0_1-O-15